Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge. We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.
LÄS MER
